Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Celebrities Urge Fans to Join the END7 Campaign


News provided by

Sabin Vaccine Institute

26 Feb, 2013, 04:00 GMT

Share this article

Share toX

Share this article

Share toX

- New Video Builds Momentum in Global Effort to End Neglected Tropical Diseases by 2020

WASHINGTON, Feb. 26, 2013 /PRNewswire/ -- In a hard-hitting new video released today, celebrities from around the world called for support in the global effort to control and eliminate seven diseases that plague more than 1 billion people around the world, including 500 million children. In the video, international actors and musicians witness the devastation neglected tropical diseases (NTDs) cause and encourage their fans to be part of the solution.  The video is part of the END7 campaign, the first global public awareness initiative dedicated to controlling and eliminating the seven most prevalent NTDs by 2020.

Continue Reading
This image opens in the lightbox
END7: How to Shock a Celebrity. (PRNewsFoto/Sabin Vaccine Institute) (PRNewsFoto/SABIN VACCINE INSTITUTE)

(Photo: http://photos.prnewswire.com/prnh/20130225/DC65582 )

Emily Blunt ("Salmon Fishing in the Yemen," "Devil Wears Prada"); Eddie Redmayne ("Les Miserables," "My Week with Marilyn"); Tom Felton ("Harry Potter" series); Yvonne Chaka Chaka (South African pop star); Tom Hollander ("Pirates of the Caribbean," "Pride and Prejudice"); and Priyanka Chopra (leading Bollywood actress and international recording artist) are featured in the video. These celebrities join a growing cast of supporters including Katy Perry, Ewan McGregor, Alyssa Milano, Norah Jones, Rosanna Cash, Paula Abdul and Stella McCartney to help raise public awareness about NTDs.

"Until recently, I didn't even know these diseases existed," said actress Emily Blunt. "The serious disabilities and suffering they inflict on the world's poorest people is heart-wrenching. But I was inspired to join the END7 campaign because, for once, the solution is simple and available now. And the cost for treatment is so low that almost anyone can make a big difference by giving just a few pence."

END7 relies heavily on individuals spreading the word and getting involved through Facebook, Twitter and YouTube. It aims to raise the public awareness and funding required to cover the cost of distributing medicine and setting up treatment programs for NTDs. END7 is encouraging supporters to sign a pledge to inspire global policy leaders and philanthropists to take action and help end these diseases by 2020. 

It costs approximately 50 pence to treat one person against the seven most common NTDs for an entire year. Pharmaceutical companies have donated billions of pills to treat these diseases, and many programs use existing infrastructure, such as schools and community centers, as distribution points, making NTD treatment one of most cost-effective public health initiatives available today.

The seven most common NTDs—hookworm, ascariasis (roundworm), trichuriasis (whipworm), schistosomiasis (snail fever or bilharzia), lymphatic filariasis (elephantiasis), onchocerciasis (river blindness) and trachoma—infect more than one in six people worldwide, including more than 500 million children. They cause blindness, massive swelling in appendages and limbs, severe malnutrition and anemia.  NTDs prevent children from growing and learning. They reduce adults' economic productivity and ability to care for their families, keeping communities trapped in a cycle of poverty and disease.

"In India alone, nearly 700 million people are at risk for elephantiasis and more than 200 million children are at risk for worm infections," said Bollywood star Priyanka Chopra. "Through the END7 campaign, we can offer a solution that will change the lives of millions of people living in poverty in Asia and around the world. I am proud to be a part of the global effort to end these diseases."

The END7 campaign was launched in 2012 by the Global Network for Neglected Tropical Diseases, an initiative of the Sabin Vaccine Institute. Wunderman UK leads the creative direction for the campaign, which includes this latest video along with the campaign's website, Facebook hub and the previously released "Mission in a Minute" video.

"We are building a movement that allows nearly everyone to play a part in making these diseases history," said Dr. Neeraj Mistry, managing director of the Global Network for Neglected Tropical Diseases. "Since last January's London Declaration we have seen a significant increase in support for NTD control and elimination among global leaders. What we need now is for the general public to get involved in our cause."

To watch the video, entitled END7: How to Shock a Celebrity, and learn more about the END7 campaign, visit www.end7.org.

ADDITIONAL QUOTES AND INFORMATION FOR MEDIA:

Tom Felton
"I have really been impressed with the support for END7 among my fans," said Tom Felton. "END7 is unique because so little goes such a long way. Through Facebook, YouTube and Twitter, young people can donate and share the campaign with their friends. A simple social media post can make a big impact."

Eddie Redmayne
"After watching the footage of these diseases, I was compelled to learn more," said Eddie Redmayne. "While these diseases might be complicated, the solution is simple:  50 pence is all it takes to treat someone infected with up to seven of the most common NTDs."

Tom Hollander
"What struck me most about END7 is that the tools to treat these diseases are already available," said Tom Hollander. "What's missing is the public support to help get the medicine to the communities that need it most. I am proud to do my part, and urge my fans to learn about NTDs and what we can do to treat and prevent them."

Yvonne Chaka Chaka
"These diseases are very real, even if people are not talking about them" said Yvonne Chaka Chaka. "Africa carries 50 percent of the global NTD burden, and I've seen their impact first hand. The END7 campaign is sparking a global movement to end these diseases." 

About END7
END7 is an international advocacy campaign that seeks to raise the awareness and funding necessary to control and eliminate the seven most common neglected tropical diseases by 2020.  The international effort to control and eliminate NTDs has the support of a diverse group of global partners, including the World Health Organization (WHO), national governments, pharmaceutical companies, corporations and individuals. END7 is run by the Global Network for Neglected Tropical Diseases, an initiative of the Sabin Vaccine Institute.  

About NTDs
NTDs are a group of 17 parasitic and bacterial infections that are the most common afflictions of the world's poorest people. They blind, disable and disfigure their victims, trapping them in a cycle of poverty and disease. Research shows that treating NTDs lifts millions out of poverty by ensuring that children stay in school to learn and prosper; by strengthening worker productivity; and by improving maternal and child health.

About Sabin Vaccine Institute   
Sabin Vaccine Institute is a non-profit, 501(c)(3) organization of scientists, researchers, and advocates dedicated to reducing needless human suffering caused by vaccine preventable and neglected tropical diseases. Sabin works with governments, leading public and private organizations, and academic institutions to provide solutions for some of the world's most pervasive health challenges. Since its founding in 1993 in honor of the oral polio vaccine developer, Dr. Albert B. Sabin, the Institute has been at the forefront of efforts to control, treat and eliminate these diseases by developing new vaccines, advocating use of existing vaccines and promoting increased access to affordable medical treatments. For more information please visit www.sabin.org.

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.